Your search history is turned on.
Date: April 30, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Waverley Pharma Business Update Waverley Pharma Business Update WINNIPEG, MB, April 30, 2024 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV: WAVE), a Canadian pharmaceutical company, is announcing a business update. As mentioned in the previous business update dated August 2, 2023, opportunities Waverley Pharma envisioned of marketing generic oncology drugs capecitabine, t...
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Haaris Uddin, Chief Financial Officer of Waverley Pharma Inc, certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incor...
FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Larry Thiessen, Chief Executive Officer of Waverley Pharma Inc, certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are inc...
Microsoft Word - DRAFT - F2023 WAVE MD&A - 26 APR 2024 Management Discussion and Analysis (Expressed in Canadian Dollars) WAVERLEY PHARMA INC. Year ended December 31, 2023 1 BACKGROUND This Managements Discussion and Analysis (MD&A) of Waverley Pharma Inc. (Waverley or the Company) is dated April 29, 2024 and pro...
Date: April 29, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, UDDIN, Haaris, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Consolidated Financial Statements (Expressed in Canadian Dollars) WAVERLEY PHARMA INC. Year ended December 31, 2023 A member firm of Ernst & Young Global Limited Independent auditors report To the Shareholders of Waverley Pharma Inc. Opinion We have audited the consolidated financial statements of Waverley Pharma Inc. [the Company], which...
Date: April 19, 2024 Jurisdictions: All jurisdictions
April 05, 2024 324-8th Avenue SW, 8th floor Calgary AB, T2P 2Z2 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: WAVERLEY PHARMA INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual and Specia...
Date: November 27, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Haaris Uddin, Chief Financial Officer of Waverley Pharma Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Waverley Pharma Inc. (the issuer) for the interim period ended September 30,...
FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Larry Thiessen, Chief Executive Officer of Waverley Pharma Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Waverley Pharma Inc. (the issuer) for the interim period ended September 3...